iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers at ESTRO 37

Company to
showcase advanced, multi-platform electronic brachytherapy (eBx) technology in
booth 6800

Nashua, N.H.
and Barcelona, Spain (ESTRO Booth 6800) (April 19, 2018) – iCAD, Inc.
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today announced that researchers from
Hospital Universitario Miguel Servet in Zaragoza, Spain will present new
results from three clinical studies supporting the efficacy of the Xoft®
Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of
early-stage breast cancer and gynecological cancers during the European Society
for Radiotherapy & Oncology (ESTRO 37) meeting at the Barcelona
International Convention Centre in Barcelona, Spain. The Xoft System is a
proprietary eBx platform designed to deliver isotope-free (non-radioactive)
radiation therapy.

“We are
pleased that clinical results from multiple studies continue to demonstrate the
therapeutic value of this innovative treatment option,” said Ken Ferry, CEO of
iCAD. “This important new research adds to a growing body of data confirming
the significant benefits that the Xoft System offers to patients and clinicians
worldwide.”

At ESTRO 37,
clinicians from Hospital Universitario Miguel Servet will present new
preliminary findings from three studies that further demonstrate the efficacy
of the Xoft System in the treatment of early-stage breast cancer and
gynecological cancers. Since their adoption of the technology in 2015,
clinicians at Hospital Universitario Miguel Servet have treated more than 350
early-stage breast cancer and gynecological cancer patients with the Xoft
System.

“By precisely
targeting cancer cells and sparing surrounding healthy tissue, the Xoft System
has empowered our clinicians to significantly improve patient outcomes and
reduce toxicity in treating a range of cancers,” said Martin Tejedor, M.D.,
Chief of Radiation Oncology, Hospital Universitario Miguel Servet. “We are very
encouraged by our results to date with this transformative technology, and we
are committed to offering this valuable treatment option to appropriately
selected patients in Spain.”

Summarized
findings and links to the electronic data are available below.

•PO-1089:
IORT for Breast Cancer Treated with Axxent Xoft. Our Experience: Toxicity
Analysis

Preliminary
results in 136 patients treated from May 2015 to August 2016 show feasible
acute and late toxicity and good cosmetic outcomes.

•EP-1314:
Breast Treatments with Axxent Equipment. Comparison with Mammosite for Skin,
Lung and Heart Dose

Preliminary
results in 250 patients treated from May 2015 to September 2017 show no
recurrences in patients treated to date and low skin toxicity.

•EP-2226:
Toxicity Results After Treatment with Electronic Brachytherapy in Patients with
Endometrial Cancer

Preliminary
results in 94 patients treated from September 2015 to September 2017 show
targeted approach reduces toxicity to organs at risk.

The Xoft
System is FDA cleared, CE marked, and licensed in a growing number of countries
for the treatment of cancer anywhere in the body, including early-stage breast
cancer, gynecological cancers and non-melanoma skin cancer. It uses a
proprietary, miniaturized x-ray source to deliver targeted radiation directly
to the cancerous site, sparing healthy tissues and surrounding organs. The Xoft
System is highly mobile and requires minimal shielding, allowing it to be used
in a variety of clinical settings and eliminating the need for room
redesign or construction investment. For more information, please visit booth
6800 during the ESTRO 37 meeting, or www.xoftinc.com.

About iCAD,
Inc.

Headquartered
in Nashua, N.H., iCAD is a global medical technology leader providing
innovative cancer detection and therapy solutions. For more information,
visit www.icadmed.com.

About
Hospital Universitario Miguel Servet

The Hospital
was founded in 1955 with the name “Residencia Jose Antonio”. In 1971, it was
extended with the Rehabilitation, Traumatology and Burns Hospital and the
Maternity Hospital. In 1976, it undertook a multi-phase modernization program,
converting over the years to form what since 1984 has been known as the
“Hospital Miguel Servet”. In 1999, the Hospital reached the category of
University Hospital, under the name of the “Hospital Universitario Miguel
Servet”. In addition to undergraduate teaching, the hospital offers training
for residents in around forty specializations. The Hospital today is the
largest in Aragon and among the first in Spain in terms of both volume as well
as complexity. It has 1,288 installed beds, 33 operating rooms and a long list
of Units, with a reference population of over 800,000 inhabitants in the
Autonomous Community of Aragon. Every year the hospital receives 46,000
admissions, offers 800,000 consultations and performs 37,000 surgeries. The
hospital has an average occupation of over 76%, and 5,500 employees. The
hospital also has two national reference units (Burns and Multiple Sclerosis)
as well as special reference units for all of Aragon and neighboring provinces.

“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of
1995

Certain
statements contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve a number of known and unknown
risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, but are not limited to the
Company’s ability to defend itself in litigation matters, to achieve business
and strategic objectives, the risks of uncertainty of patent protection, the impact
of supply and manufacturing constraints or difficulties, uncertainty of future
sales levels, protection of patents and other proprietary rights, product
market acceptance, possible technological obsolescence of products, increased
competition, litigation and/or government regulation, changes in Medicare or
other reimbursement policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the economy or
markets served by the Company; and other risks detailed in the Company’s
filings with the Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance
on those forward-looking statements, which speak only as of the date the
statement was made. The Company is under no obligation to provide any updates
to any information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the disclosure
contained in our public filings with the Securities and Exchange Commission,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.

Contacts:

Media
Inquiries:
ARPR
Erin Bocherer, (855)-300-8209
erin@arpr.com

Investor
Relations:

LifeSci
Advisors
Jeremy Feffer, (212) 915-2568
jeremy@lifesciadvisors.com